1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Oral Antibiotics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Class
6.1 Beta Lactam and Beta Lactamase Inhibitors
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Penicillin
6.1.2.2 Cephalosporin
6.1.2.3 Others
6.1.3 Market Forecast
6.2 Quinolone
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Macrolide
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Application
7.1 Community-acquired Respiratory Tract Infections (CARTIs)
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Upper Respiratory Tract Infections (URTI)
7.1.2.2 Lower Respiratory Tract Infections (LRTIs)
7.1.3 Market Forecast
7.2 Urinary Tract Infections (UTIs)
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Dental
7.3.1 Market Trends
7.3.2 Key Segments
7.3.2.1 Combination
7.3.2.2 Monotherapies
7.3.3 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Drug Origin
8.1 Natural
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Semisynthetic
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Synthetic
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Spectrum of Activity
9.1 Broad-spectrum Antibiotic
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Narrow Spectrum Antibiotic
9.2.1 Market Trends
9.2.2 Market Forecast
10 Market Breakup by Drug Type
10.1 Branded
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Generics
10.2.1 Market Trends
10.2.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 Drivers, Restraints, and Opportunities
12.1 Overview
12.2 Drivers
12.3 Restraints
12.4 Opportunities
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Bayer AG
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Cipla Inc
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.3 Gilead Sciences Inc
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Janssen Inc. (Johnson & Johnson Services, Inc)
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.5 Pfizer Inc.
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 Roche Holding AG
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 Financials
16.3.7 Sun Pharmaceutical Industries Ltd
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Teva Pharmaceutical Industries Ltd.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
